Lupin
LUPIN
Performance
About Lupin
Lupin is a global pharmaceutical company originating in India with a broad portfolio spanning generics, biosimilars, specialty medicines, and biotech CDMO services. It maintains a worldwide manufacturing and research footprint, focusing on key therapeutic areas such as respiratory, cardiovascular, tuberculosis, and diabetes management. The company emphasizes innovation and integrated healthcare delivery across multiple markets, including India, the US, the UK, and other regions. Lupin highlights its commitment to research and development, manufacturing excellence, and social responsibility through its broader community initiatives.
Recent News
Stock Market Live: Sensex, Nifty Trade Flat with Positive Bias Amid US–Iran Tensions; Crude Spike Raises Volatility Concerns
Semaglutide Race: Torrent Grabs 38% Market Share
Lupin Receives Form 483 After USFDA Inspection of Somerset Unit
Sun Pharma to Acquire Organon for $12 Billion, Its Largest U.S. Deal Yet
Stock Market Today: Sensex Falls 114 Points, Nifty 50 Ends Above 24,300; Mid, Small-Cap Indices Jump 1%
Lupin Launches Generic Diabetes Drug in US After USFDA Approval
Lupin Secures FDA Approval for Generic Glycerol Phenylbutyrate Oral Liquid for UCDs
Generally Good Indian Pharma Companies
Morning Brief Podcast: Pharma's AI Reckoning
Generally Good Indian Pharma Companies
Lupin Shares to Be in Focus on Thursday as USFDA Approves Dapagliflozin and Metformin Tablets
Stock Market Live: Stock to Buy Today: Adani Green Energy
Sensex Jumps over 2900 Pts, Nifty Touches 24,000 Mark: Bank, Auto & Realty Stocks Lead Market Rally as RBI Hold Rates